Lineage Cell Therapeutics (LCTX) Change in Cash (2010 - 2026)

Lineage Cell Therapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.

• In Q1 2026, Change in Cash fell 343.86% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$11.9 million (down 381.18% YoY), while the FY2025 annual figure was -$5.0 million, down 148.54% from the prior year.
• Change in Cash for Q1 2026 stood at -$4.8 million, down from $347000.0 in the prior quarter.
• The five-year high for Change in Cash was $22.3 million in Q1 2022, with the low at -$46.1 million in Q3 2022.
• The 5-year median for Change in Cash is -$1.8 million (2025), against an average of -$1.2 million.
• The sharpest annual moves came in 2022 and 2023: Change in Cash slumped 3777.44% in 2022, then surged 354.34% in 2023.
• Lineage Cell Therapeutics' Change in Cash stood at -$13.4 million in 2022, then soared by 129.88% to $4.0 million in 2023, then surged by 352.1% to $18.0 million in 2024, then tumbled by 98.08% to $347000.0 in 2025, then sank by 1497.12% to -$4.8 million in 2026.
• Business Quant data shows LCTX's Change in Cash at -$4.8 million in Q1 2026, $347000.0 in Q4 2025, and -$1.8 million in Q3 2025.